Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02698475 · ClinicalTrials.gov registry record · Phase 3
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 44
- Enrollment target
NCT02698475 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 44 participants.
The verdict
NCT02698475, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ustekinumab in pediatric participants aged greater than or equal to (\>=) 6 through less than (\<) 12 years with moderate to severe chronic plaque psoriasis
Interventions
- DRUG Ustekinumab 45 mg
- DRUG Ustekinumab 90 mg
- DRUG Ustekinumab 0.75 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-05 |
| Est. Completion | 2020-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02698475
The ClinicalTrials.gov registry entry for NCT02698475 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ustekinumab 45 mg is the first listed.
NCT02698475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02698475 about?
NCT02698475 is a clinical study titled "An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age". The purpose of this study is to evaluate the efficacy and safety of ustekinumab in pediatric participants aged greater than or equal to (\>=) 6 through less than (\<) 12 years with moderate to severe chronic plaque psoriasis
What is the current status of trial NCT02698475?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 2016-05. Estimated completion is 2020-10.
What interventions are being tested in trial NCT02698475?
The interventions under investigation include: Ustekinumab 45 mg (DRUG), Ustekinumab 90 mg (DRUG), Ustekinumab 0.75 mg/kg (DRUG).
Who is sponsoring clinical trial NCT02698475?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.